Avanos Medical Secures Stockholder Approval for Acquisition by American Industrial Partners

Avanos Medical, Inc. (NYSE: AVNS), a prominent player in the medical technology landscape, has recently achieved a milestone by receiving overwhelming support from its stockholders for its acquisition by American Industrial Partners (AIP). In a special meeting held for this purpose on July 22, 2026, about 99.75% of the shares voted were in favor of the deal, amounting to nearly 75% of the total outstanding shares of Avanos common stock as of the record date of June 18, 2026.

Gary D. Blackford, the Chair of Avanos' Board, expressed gratitude towards the company's stockholders, emphasizing that this decision propels Avanos towards a bright future. He believes that this partnership with AIP will not only boost the company's operational capabilities but also provide it with greater resources necessary to tackle current healthcare challenges effectively.

As per the merger agreement, Avanos stockholders will receive $25.00 in cash for each share they own once the acquisition takes effect. All necessary regulatory approvals have already been granted, and the transaction is projected to complete by July 27, 2026, pending standard closing conditions being fulfilled.

Avanos Medical, based in Alpharetta, Georgia, is dedicated to delivering clinical solutions that significantly improve patient care. The company's innovation focuses on providing critical medical devices that assist patients transition from hospital to their homes. They are also dedicated to reducing opioid dependency while supporting patients' recovery from surgical procedures.

The decision to merge with AIP illustrates Avanos' commitment to enhancing its capacity to cater to patient needs in an evolving healthcare marketplace. The strategic advantage derived from this acquisition is expected to foster advancements in medical technology solutions and patient care, ultimately benefiting the healthcare system as a whole.

The formal culmination of this acquisition not only signals a new chapter for Avanos Medical but also reinforces the investment confidence in the healthcare sector’s direction under the aegis of American Industrial Partners. This collaboration aims to unlock new potentials within the rapidly changing landscape of medical technology.

In conclusion, the stockholder approval represents a pivotal point for Avanos Medical, allowing the company to maximize its growth trajectory and market presence. As they prepare to close this transaction, both Avanos and AIP are optimistic about the future ahead, focused on making impactful contributions to healthcare solutions worldwide.

For further information on Avanos Medical, visit avanos.com and stay connected through their social media platforms, including X (formerly Twitter), LinkedIn, and Facebook.

This acquisition stands as a testament to the evolving nature of healthcare technology, showcasing how strategic mergers can potentiate advancements designed to enhance patient well-being. The upcoming developments should be watched closely as Avanos transitions into this new phase of corporate evolution.

Disclaimer: This article may contain forward-looking statements about Avanos Medical’s future, which may differ due to various risks and uncertainties.